Literature DB >> 31813533

County-Level Variations in Receipt of Surgery for Early-Stage Non-small Cell Lung Cancer in the United States.

Helmneh M Sineshaw1, Liora Sahar2, Raymond U Osarogiagbon3, W Dana Flanders4, K Robin Yabroff2, Ahmedin Jemal2.   

Abstract

BACKGROUND: Although counties are the smallest geographic level for comprehensive health-care delivery analysis, little is known about county-level variations in receipt of curative-intent surgery for early-stage non-small cell lung cancer (NSCLC) and factors contributing to such variations in the United States.
METHODS: A total of 179,189 patients aged ≥ 35 years who were diagnosed with stage I to II NSCLC between 2007 and 2014 in 2,263 counties were identified from 39 states, the District of Columbia, and Detroit population-based cancer registries; the data were compiled by the North American Association of Central Cancer Registries. The percentage of patients who underwent surgery was calculated for each county with ≥ 20 cases. Adjusted risk ratios were generated by using generalized estimating equation models with modified Poisson regression.
RESULTS: Receipt of surgery for early-stage NSCLC during 2007 to 2014 according to county ranged from 12.8% to 48.6% in the lowest decile of counties, to 74.3% to 91.7% in the highest decile of counties. There were pockets of low surgery receipt rate counties within each state. For example, there was a 25% absolute difference between the lowest and highest surgery receipt rate counties in Massachusetts. Counties in the lowest quartile for receipt of surgery were those with a high proportion of non-Hispanic black subjects, high poverty and uninsured rates, low surgeon-to-population ratio, and nonmetropolitan status.
CONCLUSIONS: Receipt of curative-intent surgery for early-stage NSCLC varied substantially across counties in the United States, with pockets of low receipt counties in each state. Low surgery receipt counties were characterized by unfavorable area-level socioeconomic and health-care delivery factors.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  epidemiology; health-care disparities; health-care utilization; research-clinical; surgery oncology

Mesh:

Year:  2019        PMID: 31813533      PMCID: PMC6965692          DOI: 10.1016/j.chest.2019.09.016

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Anna Derrick; Matthew P Smeltzer; Raymond U Osarogiagbon
Journal:  Chest       Date:  2020-05-06       Impact factor: 9.410

Review 2.  Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research.

Authors:  Smita Bhatia; Wendy Landier; Electra D Paskett; Katherine B Peters; Janette K Merrill; Jonathan Phillips; Raymond U Osarogiagbon
Journal:  J Natl Cancer Inst       Date:  2022-07-11       Impact factor: 11.816

3.  Volume-Based Care Regionalization: Pitfalls and Challenges.

Authors:  Raymond U Osarogiagbon
Journal:  J Clin Oncol       Date:  2020-09-08       Impact factor: 50.717

4.  Surgery without preoperative histological confirmation of lung cancer: what is the current clinical practice?

Authors:  Mohammad R Ghamati; Wilson W L Li; Erik H F M van der Heijden; Ad F T M Verhagen; Ronald A Damhuis
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 3.005

5.  Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States.

Authors:  Raymond U Osarogiagbon; Helmneh M Sineshaw; Chun Chieh Lin; Ahmedin Jemal
Journal:  Chest       Date:  2020-11-14       Impact factor: 9.410

Review 6.  Narrative review of socioeconomic and racial disparities in the treatment of early stage lung cancer.

Authors:  Nathaniel Evans; Tyler Grenda; Nkosi H Alvarez; Olugbenga T Okusanya
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.